DXCM DexcomcompanySEC Filings & Insider Trading Activity 2026
Latest Dexcom (DXCM) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 12, 2026, a 10-Q quarterly report filed on October 30, 2025, an 8-K current report filed on April 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Dexcom (DXCM) (SEC CIK 1093557), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes and metabolic health management
- • New product launched: Stelo, first over-the-counter glucose biosensor for prediabetes and Type 2 diabetes adults not using insulin (U.S. launch Aug 2024)
Management Discussion & Analysis
- • Revenue $4,662M, up 16% YoY from $4,033M driven by 600K-700K net customer additions
- • Operating margin 20.0% vs 14.9%, operating income $911.8M up 52% YoY from $600.0M
Risk Factors
- • Cybersecurity risk exposure due to integration of cloud-based technology platforms increasing operational costs
- • Board Technology Committee delegation for cybersecurity risk oversight with annual compliance reviews to applicable laws and standards
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • Revenue $1.21B in Q3 2025, up 22% YoY from $994.2M in Q3 2024
- • Operating margin 20.0% vs 15.3% YoY; net income margin 23.5% vs 13.5% YoY; net income $283.8M up 111% YoY
Risk Factors
- • No newly added risk factors this quarter; risk section supplements and supersedes 2024 10-K disclosures
- • No material changes to previously disclosed risk factors; risks remain consistent with 2024 10-K filing
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Sayer returns from leave March 2, 2026, resuming Executive Chairman role; Mark Foletta steps back from interim Lead Independent Director duties
- • New comp package: $610,000 annual base salary as Executive Chairman
Item 7.01: Regulation FD Disclosure
- • Rick Osterloh appointed to Dexcom Board of Directors, effective February 26, 2026
- • Board composition change signals potential strategic direction; Osterloh's background (hardware/consumer tech at Google) relevant to Dexcom's wearable CGM business
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Board expanded to 12 directors; Rick Osterloh appointed immediately, term through 2026 Annual Meeting
- • Osterloh designated independent; assigned to Compensation Committee and Technology Committee
Annual Reports Archive10-K
AI-powered analysis of Dexcom (DXCM) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Dexcom (DXCM) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Dexcom (DXCM) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $2.9B | $3.6B | $4.0B | $4.7B |
| Gross Profit | $1.9B | $2.3B | $2.4B | $2.8B |
| Operating Income | — | $597.7M | $600.0M | $911.8M |
| Net Income | — | $541.5M | $576.2M | $836.3M |
| Gross Margin | 64.7% | 63.2% | 60.5% | 60.1% |
| Op. Margin | — | 16.5% | 14.9% | 19.6% |
| Net Margin | — | 14.9% | 14.3% | 17.9% |
| Balance Sheet | ||||
| Total Assets | — | $6.3B | $6.5B | $6.3B |
| Equity | — | $2.1B | $2.1B | $2.7B |
| ROE | — | 26.2% | 27.4% | 30.5% |
Source: XBRL financial data from Dexcom (DXCM) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 30, 2026 | — | — | — |
8-K | Mar 2, 2026 | — | Analysis | — |
8-K | Feb 26, 2026 | — | Analysis | — |
10-K | Feb 12, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 12, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
8-K | Dec 22, 2025 | — | — | |
10-Q | Oct 30, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Jul 30, 2025 | Jun 30, 2025 | Analysis | |
10-Q | May 1, 2025 | Mar 31, 2025 | — | |
10-K | Feb 18, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 24, 2024 | Sep 30, 2024 | — | |
10-Q | Jul 25, 2024 | Jun 30, 2024 | — | |
10-Q | Apr 25, 2024 | Mar 31, 2024 | — | |
10-K | Feb 8, 2024 | Dec 31, 2023 | — | |
10-Q | Oct 26, 2023 | Sep 30, 2023 | — | |
10-Q | Jul 27, 2023 | Jun 30, 2023 | — | |
10-Q | Apr 27, 2023 | Mar 31, 2023 | — | |
10-K | Feb 9, 2023 | Dec 31, 2022 | — | |
10-Q | Oct 27, 2022 | Sep 30, 2022 | — | |
10-Q | Jul 28, 2022 | Jun 30, 2022 | — | |
10-Q | Apr 28, 2022 | Mar 31, 2022 | — | |
10-K | Feb 14, 2022 | Dec 31, 2021 | — | |
10-Q | Oct 28, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 29, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest DXCM SEC filings in 2026?
Dexcom (DXCM) has filed a 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 30, 2025, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did DXCM file its most recent 10-K annual report?
Dexcom (DXCM) filed its most recent 10-K annual report on February 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view DXCM 10-Q quarterly reports?
Dexcom (DXCM)'s most recent 10-Q quarterly report was filed on October 30, 2025. SignalX displays every DXCM 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has DXCM filed recently?
Dexcom (DXCM)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find DXCM insider trading activity (Form 4)?
SignalX aggregates every DXCM Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does DXCM file with the SEC?
Dexcom (DXCM) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new DXCM filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Dexcom (DXCM).
What is DXCM's SEC CIK number?
Dexcom (DXCM)'s SEC CIK (Central Index Key) number is 1093557. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1093557 to look up all DXCM filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find DXCM return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Dexcom (DXCM) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Dexcom SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 37+ filings.